JP7848195B2 - Ｋｄｍ１ａによって媒介される疾患を治療するための医薬製剤 - Google Patents

Ｋｄｍ１ａによって媒介される疾患を治療するための医薬製剤

Info

Publication number
JP7848195B2
JP7848195B2 JP2023519794A JP2023519794A JP7848195B2 JP 7848195 B2 JP7848195 B2 JP 7848195B2 JP 2023519794 A JP2023519794 A JP 2023519794A JP 2023519794 A JP2023519794 A JP 2023519794A JP 7848195 B2 JP7848195 B2 JP 7848195B2
Authority
JP
Japan
Prior art keywords
compound
approximately
pharmaceutical composition
amount
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023519794A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023544327A (ja
JP2023544327A5 (https=
Inventor
タッパー エイミー
セラトカ カサンドラ
ソウリアック パトリシア
ヴェッド パラーグ
ヴォーラ ナムラタ
Original Assignee
イマーゴ バイオサイエンシーズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イマーゴ バイオサイエンシーズ インコーポレイテッド filed Critical イマーゴ バイオサイエンシーズ インコーポレイテッド
Publication of JP2023544327A publication Critical patent/JP2023544327A/ja
Publication of JP2023544327A5 publication Critical patent/JP2023544327A5/ja
Application granted granted Critical
Publication of JP7848195B2 publication Critical patent/JP7848195B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2023519794A 2020-10-01 2021-10-01 Ｋｄｍ１ａによって媒介される疾患を治療するための医薬製剤 Active JP7848195B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063086353P 2020-10-01 2020-10-01
US63/086,353 2020-10-01
PCT/US2021/053141 WO2022072811A1 (en) 2020-10-01 2021-10-01 Pharmaceutical formulations for treating diseases mediated by kdm1a

Publications (3)

Publication Number Publication Date
JP2023544327A JP2023544327A (ja) 2023-10-23
JP2023544327A5 JP2023544327A5 (https=) 2024-10-09
JP7848195B2 true JP7848195B2 (ja) 2026-04-20

Family

ID=80951023

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023519794A Active JP7848195B2 (ja) 2020-10-01 2021-10-01 Ｋｄｍ１ａによって媒介される疾患を治療するための医薬製剤

Country Status (10)

Country Link
US (1) US20230293495A1 (https=)
EP (1) EP4221704B1 (https=)
JP (1) JP7848195B2 (https=)
KR (1) KR20230079151A (https=)
CN (1) CN116367831A (https=)
AU (1) AU2021351536A1 (https=)
BR (1) BR112023005987A2 (https=)
CA (1) CA3193661A1 (https=)
MX (1) MX2023003783A (https=)
WO (1) WO2022072811A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250295660A1 (en) 2022-05-09 2025-09-25 Oryzon Genomics, S.A. Methods of treating nf1-mutant tumors using lsd1 inhibitors
EP4522136A1 (en) 2022-05-09 2025-03-19 Oryzon Genomics, S.A. Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors
CN120529900A (zh) 2022-11-24 2025-08-22 奥莱松基因组股份有限公司 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011529445A (ja) 2008-07-28 2011-12-08 武田薬品工業株式会社 医薬組成物
JP2018508478A (ja) 2015-02-12 2018-03-29 イマーゴ バイオサイエンシーズ インコーポレイテッド 疾患の治療のためのｋｄｍ１ａ阻害剤
JP2019514881A (ja) 2016-04-22 2019-06-06 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｌｓｄ１阻害剤の製剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962488A (en) * 1998-04-08 1999-10-05 Roberts Laboratories, Inc. Stable pharmaceutical formulations for treating internal bowel syndrome containing isoxazole derivatives
US20060089387A1 (en) * 2004-10-26 2006-04-27 Le Huang Stabilized pharmaceutical composition comprising antidiabetic agent
US20100273825A1 (en) * 2009-03-30 2010-10-28 Astellas Pharma Inc. Solid pharmaceutical composition containing solifenacin amorphous form
RU2627471C2 (ru) * 2011-09-14 2017-08-08 Селджин Корпорейшн Препараты { 2-[(1s)-1-(3-этокси-4-метоксифенил)-2-метансульфонилэтил]-3-оксо-2,3-дигидро-1h-изоиндол-4-ил} амида циклопропанкарбоновой кислоты
WO2015170237A1 (en) * 2014-05-05 2015-11-12 Torrent Pharmaceuticals Limited Stable solifenacin composition
US20190070172A1 (en) * 2015-11-05 2019-03-07 Imago Biosciences, Inc. Lysine-specific histone demethylase as a novel therapeutic target in myeloproliferative neoplasms
CN111194306B (zh) * 2016-08-16 2023-05-16 伊美格生物科学公司 用于制备kdm1a抑制剂的方法和过程
KR20220113753A (ko) * 2019-12-09 2022-08-16 이마고 바이오사이언시즈 인코포레이티드 골수증식성 신생물의 치료를 위한 리신-특이적 히스톤 데메틸라제 억제제

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011529445A (ja) 2008-07-28 2011-12-08 武田薬品工業株式会社 医薬組成物
JP2018508478A (ja) 2015-02-12 2018-03-29 イマーゴ バイオサイエンシーズ インコーポレイテッド 疾患の治療のためのｋｄｍ１ａ阻害剤
JP2019514881A (ja) 2016-04-22 2019-06-06 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｌｓｄ１阻害剤の製剤

Also Published As

Publication number Publication date
CN116367831A (zh) 2023-06-30
WO2022072811A1 (en) 2022-04-07
EP4221704A1 (en) 2023-08-09
KR20230079151A (ko) 2023-06-05
MX2023003783A (es) 2023-04-26
EP4221704A4 (en) 2024-11-06
BR112023005987A2 (pt) 2023-05-02
EP4221704B1 (en) 2025-09-24
JP2023544327A (ja) 2023-10-23
US20230293495A1 (en) 2023-09-21
CA3193661A1 (en) 2022-04-07
AU2021351536A1 (en) 2023-05-04

Similar Documents

Publication Publication Date Title
RU2363450C2 (ru) Таблетка с высоким содержанием лекарственного препарата
EP3509581B1 (en) Formulations of (r)-2-amino-3-phenylpropyl carbamate
JP7848195B2 (ja) Ｋｄｍ１ａによって媒介される疾患を治療するための医薬製剤
US20030147950A1 (en) Modified release tamsulosin tablets
US11452694B2 (en) High concentration dosage forms of pridopidine
US20120219626A1 (en) Pharmaceutical Compositions of Sevelamer
TR201902435T4 (tr) DGAT1 inhibitör içeren farmasötik bileşimler.
MXPA05006513A (es) Farmaco solido para uso oral.
US20260060922A1 (en) Oral pharmaceutical composition comprising carbamate compound and preparation method therefor
US9572806B2 (en) Elution-stabilized preparation
BR112020019425A2 (pt) Composição farmacêutica compreendendo meta-arsenito e método de fabricação
US9682045B2 (en) Stable pharmaceutical compositions of thyroid hormone drug
EP4424303A1 (en) Lenvatinib composition with improved bioavailability
US20240100088A1 (en) Novel formulation for treating copper metabolism-associated diseases or disorders
EA051661B1 (ru) Фармацевтическая композиция для лечения заболеваний, опосредованных kdm1a
CZ20031899A3 (en) Pharmaceutical tablet comprising paroxetine mesylate
JP7608444B2 (ja) インドールアミン２，３－ジオキシゲナーゼ阻害剤の医薬製剤
RU2810575C1 (ru) Фармацевтическая композиция, включающая мемантин и цитиколин, а также лекарственная форма на основе указанной фармацевтической композиции, включающей мемантин и цитиколин, способ ее получения и применение лекарственной формы на основе фармацевтической композиции, включающей мемантин и цитиколин
WO2026067737A1 (zh) 三唑类化合物的药物制剂及其制备方法
EP4736851A1 (en) Levodopa-benserazide hydrochloride composition and preparation therefor
JP2022536955A (ja) ジクロフェナミド組成物及び使用方法
WO2025206292A1 (ja) アコチアミド又はその塩高含有錠剤
WO2025265110A1 (en) Oral pharmaceutical compositions comprising a naphthyridine compound
JP2025036080A (ja) グアンファシンを含む医薬組成物及びその製造方法
JP2025524357A (ja) 多数の顆粒

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241001

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241001

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251209

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260317

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260408

R150 Certificate of patent or registration of utility model

Ref document number: 7848195

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150